Table 2.

Observed and expected rates for serous/serous-like endometrial cancer in BRCA mutation carriers

	Expected	Observed	O/E	95% Confidence Interval of the O/E	p	Follow Up (Woman-Years)
All Participants (N=1083)	0.34	5	14.8	4.81 – 34.6	<0.001	6376.5
BRCA1 (N=627)	0.18	4	22.2	6.05 – 56.9	<0.001	3781.0
BRCA2 (N=453)	0.16	1	6.37	0.16 – 35.5	0.15	2579.7
Prior Breast Cancer
Yes (N=727)	0.26	4	15.5	4.22 – 39.7	<0.001	4434.7
No (N=356)	0.08	1	12.6	0.32 – 70.3	0.08	1941.8
Tamoxifen Exposure
Yes (N=273)	0.12	3	24.4	5.03 – 71.3	<0.001	1878.8
No (N=655)	0.18	2	11.3	1.37 – 40.8	0.01	3738.8